Kabra Drugs Board approves new director, business diversification
Kabra Drugs Ltd's Board of Directors, in a meeting on April 21, 2026, approved the appointment of Ms. Monam Kapoor as an Additional Director, designated as Non-Executive and Independent Director, for a five-year term. The Board also approved significant business diversification into Drones & Defence equipment, Artificial Intelligence technologies, Hospital/E-Pharmacy/Medical equipment, Hospitality, Dairy products, and Agro farms. This diversification necessitates an alteration of the Main Objects clause in the Memorandum of Association (MOA), which will be subject to shareholder approval. A Postal Ballot was approved for the company's name change and the MOA alteration. The e-voting for the postal ballot will commence on May 9, 2026, and conclude on June 8, 2026.
Key Highlights
- Ms. Monam Kapoor appointed as Independent Director for a five-year term.
- Company to diversify into Drones, AI, Healthcare, Hospitality, Dairy, and Agro sectors.
- Main Objects clause of MOA to be altered to reflect new business segments.
- Postal Ballot approved for company name change and MOA alteration.
- E-voting for postal ballot scheduled from May 9 to June 8, 2026.